NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $34.07 -0.55 (-1.59%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$33.84 -0.23 (-0.69%) As of 04/3/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About BridgeBio Pharma Stock (NASDAQ:BBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$33.30▼$34.8650-Day Range$31.03▼$37.5952-Week Range$21.62▼$39.47Volume2.42 million shsAverage Volume2.21 million shsMarket Capitalization$6.48 billionP/E RatioN/ADividend YieldN/APrice Target$52.64Consensus RatingModerate Buy Company OverviewBridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Read More… Remove Ads BridgeBio Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreBBIO MarketRank™: BridgeBio Pharma scored higher than 92% of companies evaluated by MarketBeat, and ranked 58th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($3.67) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.19% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 1.81%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.31 Percentage of Shares Shorted15.19% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in BridgeBio Pharma has recently decreased by 1.81%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.83 News SentimentBridgeBio Pharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for BridgeBio Pharma this week, compared to 8 articles on an average week.Search InterestOnly 3 people have searched for BBIO on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $326,958,651.00 in company stock.Percentage Held by Insiders24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Stock News HeadlinesGenetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockMarch 8, 2025 | insidertrades.comBridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO)April 2 at 2:17 AM | americanbankingnews.comBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.April 4, 2025 | Stansberry Research (Ad)BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Redburn AtlanticApril 1 at 2:23 AM | americanbankingnews.comBridgeBio reports pre-specified subgroup analysis of ATTRibute-CM trialMarch 31, 2025 | markets.businessinsider.comRedburn Atlantic Initiates Coverage of BridgeBio Pharma (BBIO) with Buy RecommendationMarch 31, 2025 | msn.comBridgeBio initiated with a Buy at Redburn AtlanticMarch 31, 2025 | markets.businessinsider.comAcoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CMMarch 31, 2025 | globenewswire.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $27.44 at the beginning of the year. Since then, BBIO stock has increased by 24.2% and is now trading at $34.07. View the best growth stocks for 2025 here. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) issued its earnings results on Thursday, February, 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by $0.22. The business earned $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings2/20/2025Today4/04/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year FoundedN/APrice Target and Rating Average Stock Price Target$52.64 High Stock Price Target$95.00 Low Stock Price Target$45.00 Potential Upside/Downside+54.5%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-535,760,000.00 Net Margins-241.44% Pretax Margin-244.34% Return on EquityN/A Return on Assets-75.69% Debt Debt-to-Equity RatioN/A Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual Sales$221.90 million Price / Sales29.20 Cash FlowN/A Price / Cash FlowN/A Book Value($7.71) per share Price / Book-4.42Miscellaneous Outstanding Shares190,189,000Free Float143,288,000Market Cap$6.48 billion OptionableOptionable Beta1.08 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BBIO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.